Cargando…
Biomarker discovery for personalized therapy selection in inflammatory bowel diseases: Challenges and promises
The past decades witnessed a significant stride in deciphering the pathophysiology of inflammatory bowel disease, which further advanced drug development adding several new biologicals and small molecules to the arsenal of available therapies. Surprisingly, this wealth in therapeutic options did not...
Autores principales: | Alsoud, Dahham, Vermeire, Séverine, Verstockt, Bram |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8818904/ https://www.ncbi.nlm.nih.gov/pubmed/35146421 http://dx.doi.org/10.1016/j.crphar.2022.100089 |
Ejemplares similares
-
Unmet needs in inflammatory bowel disease
por: Revés, Joana, et al.
Publicado: (2021) -
User's guide to JAK inhibitors in inflammatory bowel disease
por: Spiewak, Ted A., et al.
Publicado: (2022) -
Managing complex perianal disease after anti-TNF failure: Where to go next?
por: Yzet, Clare, et al.
Publicado: (2022) -
When disease extent is not always a key parameter: Management of refractory ulcerative proctitis
por: Michalopoulos, Georgios, et al.
Publicado: (2021) -
Positioning biologics in the treatment of IBD: A practical guide – Which mechanism of action for whom?
por: Juillerat, Pascal, et al.
Publicado: (2022)